cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.26071/603e59c5-1edb-47b5
title: CTD Data for the 2024 BioDiv Spring Cruise in the Saint-Lawrence Gulf
title: Données CTD de la mission printemps BioDiv 2024 dans le golfe du Saint-Laurent

description: The aim of the BioDiv (id : 2024_06) mission is to characterize phytoplankton and zooplankton in the coastal zone of the northwestern Gulf of St. Lawrence.

As part of this spring mission, CTD (conductivity, temperature, depth) vertical profiles were carried out at 4 sites, each comprising 3 to 4 stations, between Baie-Trinité and Sept-Iles (Quebec North Shore). The CTD was also equipped with sensors to measure dissolved oxygen, turbidity and pH in the water column.

In addition, discrete water samples were taken at various stations and depths (surface for all stations, intermediate and bottom when depth is greater than 10m) to provide additional information on the water masses (concentrations of nutrients NO2+NO3, PO4, SiO2, dissolved and total carbon, chlorophyll a and phaeopigment, concentration of phycotoxins, concentration of bacteria, pico- and nanoplankton, flagellates).

Phytoplankton were also sampled using a 20µm net and Niskin bottles. Different size classes of zooplankton were collected with 63µm, 200µm and 333 or 500µm nets.

This dataset is part of the EDMS-ISMER-QO collection, as well as the Coastal Environmental Baseline Program Initiative under the Oceans Protection Plan of Fisheries and Oceans Canada
description: Le but de la mission BioDiv (id : 2024_06) est la caractérisation du phytoplancton et du zooplancton de la zone côtière du nord-ouest du golfe du Saint-Laurent.

Dans le cadre de cette mission printanière, des profils verticaux CTD (conductivité, température, profondeur), répartis sur 4 sites comprenant 3 à 4 stations chacun, entre Baie-Trinité et Sept-Iles (Côte-Nord du Québec), ont été réalisés. La CTD était également équipée de capteurs pour mesurer l'oxygène dissous, la turbidité et le pH dans la colonne d'eau. 

De plus, des échantillons discrets d’eau ont été réalisés à différentes stations et profondeurs (surface pour toutes les stations, intermédiaire et fond quand la profondeur est supérieure à 10m) dans le but d'apporter des informations supplémentaires sur les masses d'eau (concentrations en nutriments NO2+NO3, PO4, SiO2, en carbone dissous et carbone total, en chlorophylle a et phaeopigment, en concentration de phycotoxines, en concentration de bactéries, pico- et nanoplancton, flagellés).

De plus, le phytoplancton a été échantillonné avec un filet de 20µm et des bouteilles Niskin. Différentes classes de taille de zooplancton ont été récoltées avec des filets de 63µm, 200µm et 333 ou 500µm.

Ce jeu de données fait partie de la collection SGDE-ISMER-QO, ainsi que du Programme sur les données environnementales côtières de référence de Pêches et Océans Canada dans le cadre du Plan de protection des océans
DOI: 10.34740/kaggle/dsv/13720019
title: Peer-to-Peer Boliviano (BOB) Exchange Data
DOI: 10.15468/dl.n7vbmv
title: Occurrence Download

description: A dataset containing 196132 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Specimen",
 "Continent is Europe",
 "Country is Czechia",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 196132 records from 494 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0030970-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.17601108
title: D-PLACE dataset derived from Murdock et al. 1999 'Ethnographic Atlas'

description: Cite the source of the dataset as:




Murdock, G. P., R. Textor, H. Barry, III, D. R. White, J. P. Gray, and W. T. Divale. 1999. Ethnographic Atlas. World Cultures 10:24-136 (codebook)
DOI: 10.6084/m9.figshare.29381171
title: <b>Methane-</b><b>d</b><b>riven </b><b>w</b><b>arming </b><b>f</b><b>eedback of </b><b>a</b><b>lgal </b><b>b</b><b>looms: </b><b>Carbon dioxide-e</b><b>quivalent </b><b>e</b><b>vidence from eutrophic Lake Taihu, China</b>

description: In eutrophic lakes, algae sequester atmospheric carbon dioxide (CO<sub>2</sub>) and convert it into organic carbon (OC). However, most of this highly biodegradable endogenous OC is eventually decomposed into CO<sub>2</sub> and the potent greenhouse gas methane (CH<sub>4</sub>), potentially offsetting the initial carbon sink effect. In this study, CO<sub>2</sub>-equivalent (CO<sub>2</sub>-eq) was used as a proxy to quantify the net change from initial CO<sub>2</sub> sequestration to subsequent CO<sub>2</sub> and CH<sub>4</sub> release, and a dataset of 3,223 records was used to train machine learning models predicting the impacts of future climate warming and lake management strategies on algal net CO<sub>2</sub>-eq in Lake Taihu, a highly eutrophic lake in China.
DOI: 10.6084/m9.figshare.29381171.v1
title: <b>Methane-</b><b>d</b><b>riven</b><b> </b><b>w</b><b>arming</b><b> </b><b>f</b><b>eedback of</b><b> </b><b>a</b><b>lgal</b><b> </b><b>b</b><b>looms:</b><b> </b><b>CO</b><sub><strong>2</strong></sub><b>-</b><b>e</b><b>quivalent</b><b> </b><b>e</b><b>vidence from eutrophic Lake Taihu, China</b>

description: In eutrophic lakes, algae sequester atmospheric carbon dioxide (CO<sub>2</sub>) and convert it into organic carbon (OC). However, most of this highly biodegradable endogenous OC is eventually decomposed into CO<sub>2</sub> and the potent greenhouse gas methane (CH<sub>4</sub>), potentially offsetting the initial carbon sink effect. In this study, CO<sub>2</sub>-equivalent (CO<sub>2</sub>-eq) was used as a proxy to quantify the net change from initial CO<sub>2</sub> sequestration to subsequent CO<sub>2</sub> and CH<sub>4</sub> release, and a dataset of 3,223 records was used to train machine learning models predicting the impacts of future climate warming and lake management strategies on algal net CO<sub>2</sub>-eq in Lake Taihu, a highly eutrophic lake in China.
DOI: 10.6084/m9.figshare.29381171.v2
title: <b>Methane-</b><b>d</b><b>riven </b><b>w</b><b>arming </b><b>f</b><b>eedback of </b><b>a</b><b>lgal </b><b>b</b><b>looms: </b><b>Carbon dioxide-e</b><b>quivalent </b><b>e</b><b>vidence from eutrophic Lake Taihu, China</b>

description: In eutrophic lakes, algae sequester atmospheric carbon dioxide (CO<sub>2</sub>) and convert it into organic carbon (OC). However, most of this highly biodegradable endogenous OC is eventually decomposed into CO<sub>2</sub> and the potent greenhouse gas methane (CH<sub>4</sub>), potentially offsetting the initial carbon sink effect. In this study, CO<sub>2</sub>-equivalent (CO<sub>2</sub>-eq) was used as a proxy to quantify the net change from initial CO<sub>2</sub> sequestration to subsequent CO<sub>2</sub> and CH<sub>4</sub> release, and a dataset of 3,223 records was used to train machine learning models predicting the impacts of future climate warming and lake management strategies on algal net CO<sub>2</sub>-eq in Lake Taihu, a highly eutrophic lake in China.
DOI: 10.6084/m9.figshare.20201099
title: squamate genome annotation liftovers

description: Various genome annotation liftovers decribed in "Pinto et al. (2023)  A lizard is never late: squamate genomics as a recent catalyst for understanding microchromosome and sex chromosome evolution." using the program Liftoff. If you use these in your work, please cite the above publication (Pinto et al. 2023), the Liftoff program (Shumate et al. 2020), and both version of the genome used for annotating (if possible).
DOI: 10.6084/m9.figshare.20201099.v1
title: squamate genome annotation liftovers

description: Various genome annotation liftovers decribed in "Pinto et al. (2023)  A lizard is never late: squamate genomics as a recent catalyst for understanding microchromosome and sex chromosome evolution." using the program Liftoff. If you use these in your work, please cite the above publication (Pinto et al. 2023), the Liftoff program (Shumate et al. 2020), and both version of the genome used for annotating (if possible).
DOI: 10.15468/dl.s2tagc
title: Occurrence Download

description: A dataset containing 1501 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Carijoa riisei"
 ]
}

 The dataset includes 1501 records from 60 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0030992-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.y895b4
title: Occurrence Download

description: A dataset containing 11 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Hylodes amnicola"
 ]
}

 The dataset includes 11 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0030994-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.v8n8zq
title: Occurrence Download

description: A dataset containing 3118 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Meetnetten.be - Transects for fire salamanders in Flanders, Belgium"
 ]
}

 The dataset includes 3118 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0030993-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.8cksj7
title: Occurrence Download

description: A dataset containing 9476 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Meetnetten.be - Transects for dragonflies in Flanders, Belgium"
 ]
}

 The dataset includes 9476 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0030991-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.17601112
title: Submitted Galaxy Scores to the Gravitational Wave Treasure Map for event MS251113n Initial

description: Attached in a .json file is the ranked galaxy information within the contour region of the EM counterpart search associated with the gravitational wave event MS251113n Initial. A reference to these calculations can be found here: https://ui.adsabs.harvard.edu/abs/2017ApJ...848L..33A/abstract
DOI: 10.5281/zenodo.17601111
title: Submitted Galaxy Scores to the Gravitational Wave Treasure Map for event MS251113n Initial

description: Attached in a .json file is the ranked galaxy information within the contour region of the EM counterpart search associated with the gravitational wave event MS251113n Initial. A reference to these calculations can be found here: https://ui.adsabs.harvard.edu/abs/2017ApJ...848L..33A/abstract
DOI: 10.6084/m9.figshare.30085783.v6
title: <b>Data support</b>

description: Properties
DOI: 10.6084/m9.figshare.29003801
title: Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China

description: Metastatic urothelial carcinoma (mUC) is challenging to treat, with 37% of patients failing first-line therapy. Effective second-line treatments, like Erdafitinib, are crucial. This study evaluates the cost-effectiveness of Erdafitinib as a second-line treatment for mUC from US and Chinese payer perspectives. A Markov model was developed to project costs, life years, and quality-adjusted life years (QALYs) over lifetime. Data were collected from December 2023 to December 2024 for up-to-date estimates and were obtained from literature, health databases, and clinical trials.. The model was run to project long-term outcomes for both the United States and China. In the United States, Erdafitinib provides an additional 0.467 QALYs at a cost of $238,294.2 per QALY, which exceeds the $150,000 per QALY willingness-to-pay threshold. For China, when the cost of Erdafitinib is below $6.9 or $14 per milligram, there is a 90% probability that its incremental cost-effectiveness ratio will be below $38,223 or $84,966 per QALY, respectively. From the perspective of U.S. payers, Erdafitinib as a second-line treatment for mUC is not cost-effective. From the perspective of China, the cost-effectiveness of Erdafitinib is highly sensitive to its price, which could provide a reference for healthcare reimbursement negotiations.
DOI: 10.6084/m9.figshare.29003801.v1
title: Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China

description: Metastatic urothelial carcinoma (mUC) is challenging to treat, with 37% of patients failing first-line therapy. Effective second-line treatments, like Erdafitinib, are crucial. This study evaluates the cost-effectiveness of Erdafitinib as a second-line treatment for mUC from US and Chinese payer perspectives. A Markov model was developed to project costs, life years, and quality-adjusted life years (QALYs) over lifetime. Data were collected from December 2023 to December 2024 for up-to-date estimates and were obtained from literature, health databases, and clinical trials.. The model was run to project long-term outcomes for both the United States and China. In the United States, Erdafitinib provides an additional 0.467 QALYs at a cost of $238,294.2 per QALY, which exceeds the $150,000 per QALY willingness-to-pay threshold. For China, when the cost of Erdafitinib is below $6.9 or $14 per milligram, there is a 90% probability that its incremental cost-effectiveness ratio will be below $38,223 or $84,966 per QALY, respectively. From the perspective of U.S. payers, Erdafitinib as a second-line treatment for mUC is not cost-effective. From the perspective of China, the cost-effectiveness of Erdafitinib is highly sensitive to its price, which could provide a reference for healthcare reimbursement negotiations.
DOI: 10.6084/m9.figshare.30480567
title: Tapering of inhaled corticosteroids in stable T2-low asthma: a randomized trial of symptom- and biomarker trajectories

description: To investigate whether tapering of inhaled corticosteroids (ICSs) is non-inferior to standard of care (SoC) in asthma patients with a stable type 2 (T2)-low inflammatory profile, generally considered less responsive to ICS therapy, and to describe symptom and biomarker trajectories during tapering. This randomized, controlled, open-label multicenter trial conducted across specialist centers between 2022 and 2024 recruited adult asthma patients with persistently low T2 biomarkers, defined as blood eosinophils &lt;0.15 × 10<sup>9</sup>/L, fractional exhaled nitric oxide (FeNO) &lt;25 ppb, and non-allergic phenotype. Patients’ adherent to medium- or high-dose ICS were randomized 1:1 to either ICS tapering (50% reduction at randomization and withdrawal after 8 weeks) or continued SoC. The primary endpoint was change in Asthma Control Questionnaire (ACQ) score at 16 weeks. Secondary endpoints included changes in blood and sputum eosinophils, FeNO, periostin, and lung function. Recruitment proved challenging as only 20 of 2766 screened patients met eligibility criteria, leading to early study termination. Median ACQ remained stable in the tapering group (0 [–0.14; 0.5]) and improved modestly in the SoC group (–0.44 [–0.9; −0.11]; <i>p</i> = 0.211). FeNO (<i>p</i> = 0.038) and periostin (<i>p</i> = 0.031) increased with tapering but remained within the T2 low range. Minimal changes were observed in blood eosinophils (<i>p</i> = 0.3) and FEV<sub>1</sub> (<i>p</i> = 0.7). Premature trial termination due to recruitment challenges reflects the rarity of stable T2-low asthma. ICS tapering was not associated with greater symptom deterioration compared to SoC, although non-inferiority was not demonstrated.
DOI: 10.6084/m9.figshare.30480567.v2
title: Tapering of inhaled corticosteroids in stable T2-low asthma: a randomized trial of symptom- and biomarker trajectories

description: To investigate whether tapering of inhaled corticosteroids (ICSs) is non-inferior to standard of care (SoC) in asthma patients with a stable type 2 (T2)-low inflammatory profile, generally considered less responsive to ICS therapy, and to describe symptom and biomarker trajectories during tapering. This randomized, controlled, open-label multicenter trial conducted across specialist centers between 2022 and 2024 recruited adult asthma patients with persistently low T2 biomarkers, defined as blood eosinophils &lt;0.15 × 10<sup>9</sup>/L, fractional exhaled nitric oxide (FeNO) &lt;25 ppb, and non-allergic phenotype. Patients’ adherent to medium- or high-dose ICS were randomized 1:1 to either ICS tapering (50% reduction at randomization and withdrawal after 8 weeks) or continued SoC. The primary endpoint was change in Asthma Control Questionnaire (ACQ) score at 16 weeks. Secondary endpoints included changes in blood and sputum eosinophils, FeNO, periostin, and lung function. Recruitment proved challenging as only 20 of 2766 screened patients met eligibility criteria, leading to early study termination. Median ACQ remained stable in the tapering group (0 [–0.14; 0.5]) and improved modestly in the SoC group (–0.44 [–0.9; −0.11]; <i>p</i> = 0.211). FeNO (<i>p</i> = 0.038) and periostin (<i>p</i> = 0.031) increased with tapering but remained within the T2 low range. Minimal changes were observed in blood eosinophils (<i>p</i> = 0.3) and FEV<sub>1</sub> (<i>p</i> = 0.7). Premature trial termination due to recruitment challenges reflects the rarity of stable T2-low asthma. ICS tapering was not associated with greater symptom deterioration compared to SoC, although non-inferiority was not demonstrated.
DOI: 10.6084/m9.figshare.30480567.v1
title: Tapering of inhaled corticosteroids in stable T2-low asthma: A randomized trial of symptom- and biomarker trajectories

description: Objective To investigate whether tapering of inhaled corticosteroids (ICS) is non-inferior to standard of care (SoC) in asthma patients with a stable T2-low inflammatory profile, generally considered less responsive to ICS therapy, and to describe symptom and biomarker trajectories during tapering. Methods This randomized, controlled, open-label multicenter trial conducted across specialist centers between 2022-2024 recruited adult asthma patients with persistently low T2 biomarkers, defined as blood eosinophils &lt;0.15 × 10<sup>9</sup>/L, fractional exhaled nitric oxide (FeNO) &lt;25 ppb, and non-allergic phenotype. Patients’ adherent to medium- or high-dose ICS were randomized 1:1 to either ICS tapering (50% reduction at randomization and withdrawal after 8 weeks) or continued standard of care (SoC). The primary endpoint was change in Asthma Control Questionnaire (ACQ) score at 16 weeks. Secondary endpoints included changes in blood and sputum eosinophils, FeNO, periostin, and lung function. Results Recruitment proved challenging as only 20 of 2766 screened patients met eligibility criteria, leading to early study termination. Median ACQ remained stable in the tapering group (0 [–0.14; 0.5]) and improved modestly in the SoC group (–0.44 [–0.9; –0.11]; p = 0.211). FeNO (p = 0.038) and periostin (p = 0.031) increased with tapering but remained within the T2 low range. Minimal changes were observed in blood eosinophils (p = 0.3) and FEV<sub>1</sub> (p = 0.7). Conclusion Premature trial termination due to recruitment challenges reflects the rarity of stable T2-low asthma. ICS tapering was not associated with greater symptom deterioration compared to SoC, although non-inferiority was not demonstrated.
DOI: 10.6084/m9.figshare.30233718
title: Platform-of-1: A Bayesian Adaptive N-of-1 Trial Design for Identifying an Optimal Treatment Among Multiple Candidates

description: The process of determining an individual’s optimal treatment can be laborious. In this article, we develop a Bayesian clinical trial design, called the <i>Platform-of-1</i>, to identify this treatment among multiple candidates. We use a modified Bayesian adaptive randomization algorithm to shift the allocation probability toward a promising treatment, which incorporates decision rules to facilitate quicker decisions leading to shorter trials. Simulation results indicate that our adaptive design can reliably assign the optimal treatment at a higher frequency and achieve higher power than an equivalent design using fixed randomization. Furthermore, we show that serial correlation can greatly influence the performance of N-of-1 trials and offer recommendations to address this. Finally, we provide software and a Shiny interface to simulate and implement our design.
DOI: 10.6084/m9.figshare.30233718.v2
title: Platform-of-1: A Bayesian Adaptive N-of-1 Trial Design for Identifying an Optimal Treatment Among Multiple Candidates

description: The process of determining an individual’s optimal treatment can be laborious. In this article, we develop a Bayesian clinical trial design, called the <i>Platform-of-1</i>, to identify this treatment among multiple candidates. We use a modified Bayesian adaptive randomization algorithm to shift the allocation probability toward a promising treatment, which incorporates decision rules to facilitate quicker decisions leading to shorter trials. Simulation results indicate that our adaptive design can reliably assign the optimal treatment at a higher frequency and achieve higher power than an equivalent design using fixed randomization. Furthermore, we show that serial correlation can greatly influence the performance of N-of-1 trials and offer recommendations to address this. Finally, we provide software and a Shiny interface to simulate and implement our design.
DOI: 10.6084/m9.figshare.30233718.v1
title: Platform-of-1: a Bayesian adaptive N-of-1 trial design for identifying an optimal treatment among multiple candidates

description: The process of determining an individual’s optimal treatment can be laborious. In this article, we develop a Bayesian clinical trial design, called the <i>Platform-of-1</i>, to identify this treatment among multiple candidates. We use a modified Bayesian adaptive randomization algorithm to shift the allocation probability towards a promising treatment, which incorporates decision rules to facilitate quicker decisions leading to shorter trials. Simulation results indicate that our adaptive design can reliably assign the optimal treatment at a higher frequency and achieve higher power than an equivalent design using fixed randomization. Furthermore, we show that serial correlation can greatly influence the performance of N-of-1 trials and offer recommendations to address this. Finally, we provide software and a Shiny interface to simulate and implement our design.
DOI: 10.15468/dl.cbbksb
title: Occurrence Download

description: A dataset containing 1315188 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Pieridae",
 "Country is France",
 "HasCoordinate is true"
 ]
}

 The dataset includes 1315188 records from 5444 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0030964-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5064/f6g2petf/nuqu6a
title: Moore-et-al_IN_0721_LTC-Vacine-Fact-Sheet-7.13.21.pdf
DOI: 10.5064/f6g2petf/ict0es
title: Moore-et-al_IN_1220_Is it safe to vaccinate people who are asymptomatic carriers_ – IN.gov.pdf
DOI: 10.5064/f6g2petf/nvo9j5
title: Moore-et-al_IN_1220_What are the ingredients in the Pfizer-BioNTech COVID-19 vaccine_ – IN.gov.pdf
DOI: 10.5064/f6g2petf/gihbtd
title: Moore-et-al_IN_0821_Are there Vaccine Information Sheets (VIS) for the vaccines_ – IN.gov.pdf